Treatment with estrogens alone in women without a uterus or in combination with progestins (PG) in women with a uterus is the most effective treatment for vasomotor symptoms in the peri or postmenopausal period. However, PGs differ by their biological activities, and it is likely that not all PGs will display a class effect. The type of PG is important regarding tolerance and cardiovascular and breast cancer risk. Some studies indicate that micronized progesterone (P) is safer than synthetic PGs with an acceptable metabolic profile. For that purpose, we conducted a narrative review on the balance between benefit/risk using P versus PGs in menopause hormone therapy (MHT) to aid clinician to choose the best regimens, specifically the PG component of hormone therapy, for women with bothersome menopausal symptoms and with a uterus.
1 January 2024 in Arquivos Brasileiros de Cardiologia
1. Introdução Após a publicação dos resultados de ensaio clínico realizado pelo Women’s Health Initiative (WHI) em 2002, demonstrando que há mais riscos do que benefícios para a saúde feminina com a utilização de estrogênio (isolado ou combinado a progestagênio) para o controle dos sinais e sintomas da menopausa, houve uma diminuição progressiva e sustentada na prescrição desses medicamentos.– Nos Estados Unidos, havia ocorrido um aumento de prescrições da terapia hormonal da menopausa (THM) de 16 milhões em 1966 para [...] 1. Introdução Após a publicação dos resultados de ensaio clínico realizado pelo Women’s Health Initiative (WHI) em 2002, demonstrando que há mais riscos do que benefícios para a saúde feminina com a utilização de estrogênio (isolado ou combinado a progestagênio) para o controle dos sinais e sintomas da menopausa, houve uma diminuição progressiva e sustentada na prescrição desses medicamentos.– Nos Estados Unidos, havia ocorrido um aumento de prescrições da terapia hormonal da menopausa (THM) de 16 milhões em 1966 para
Dementia is a major public health problem. Estrogen is a regulator of the central nervous system and its deficit could be involved in cognitive decline in older women.This study aimed to evaluate t... 背景:痴呆症是一个重要的公共卫生问题。雌激素是中枢神经系统的调节器, 老年女性认知能力下降可能与雌激素缺乏有关。目的:探讨双侧卵巢切除术、绝经激素治疗(MHT)等因素与轻度认知功能损害(MCI)的关系。方法:病例对照研究纳入来自6个拉丁美洲国家941名, 60岁及以上健康的绝经后女性。记录个人和家庭数据, 使用蒙特利尔认知评估测试(MoCA)评估MCI。结果:平均年龄为66.1±5.8岁, ...
Objective: This study aims to evaluate the knowledge, attitudes, and practices of Brazilian women regarding menopause, related symptoms, and the use of hormone therapy, including indications and contraindications. Methods: A cross-sectional study was conducted between 2022/07/18 and 2023/10/01, involving women aged 40–65 years from various cities in Minas Gerais, São Paulo, and other regions of Brazil. A structured KAP (Knowledge, Attitudes, and Practices) Survey was used to assess sociodemographic characteristics, the prevalence of menopausal symptoms, and the participants’ knowledge and practices concerning Menopause Hormone Therapy (MHT). Results: The median age of the women surveyed was 50 years; 55.4% were postmenopausal (median age 55), and 44.6% were premenopausal (median age 45). The data indicate limited knowledge about menopause among Brazilian women. Less than one-third (30.3%) expressed satisfaction with the information they had received regarding menopause and available treatment options. Furthermore, 92.97% of participants demonstrated little or no knowledge of hormone therapy. Nearly 27% were unaware of MHT, and 22% opposed its use. Only 29% reported current use of MHT, with common reasons for discontinuation including fear of side effects and contraindications advised by gynecologists. Conclusion: The findings indicate that many Brazilian women have insufficient knowledge about menopause and hormone therapy. Furthermore, a lack of information and training among healthcare providers may lead to the low utilization of menopausal hormone therapy (MHT). To effectively address menopausal symptoms and empower women to make informed choices about hormone therapy, it is crucial to improve access to accurate information and enhance the training of healthcare providers.
1 January 2024 in Arquivos Brasileiros de Cardiologia
1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs.– In the United States, there was an increase in the prescription of menopausal hormone therapy (MHT) from 16 million in 1966 to 90 million in 1999,– [...] 1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs.– In the United States, there was an increase in the prescription of menopausal hormone therapy (MHT) from 16 million in 1966 to 90 million in 1999,–
The global pandemic of novel coronavirus disease 2019 has transformed health care around the world. Physicians and health-care providers face a great challenge regarding medical management notably women going through the perimenopause or those who are postmenopausal, some of them with medical comorbidities. Cancer care and screening have been disproportionately affected by COVID-19 which may have direct effects on oncological treatments. Furthermore, a major concern during the periods of social isolation involves the relationship between couples. Our attention on health and health care during this unprecedented crisis should reflect this reality, and I believe we can learn extraordinary lessons.